Stock RIGL RIGEL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Rigel Pharmaceuticals, Inc.

Equities

RIGL

US7665596034

Market Closed - Nasdaq
Other stock markets
 21:00:00 30/04/2024 BST 		5-day change 1st Jan Change
1.05 USD -1.87% Intraday chart for Rigel Pharmaceuticals, Inc. -7.89% -27.59%
04-12 Rigel Pharmaceuticals, Inc. Enters into Amendment No. 4 to that Certain Credit and Security Agreement CI
03-12 Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
PR
Rigel Pharmaceuticals : March 2024
PU
Rigel Pharmaceuticals, Inc. Enters into Amendment No. 4 to that Certain Credit and Security Agreement
CI
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PR
Rigel Announces Publication of Data on REZLIDHIA in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia and Lymphoma
AQ
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
PR
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer
CI
Citigroup Adjusts Rigel Pharmaceuticals' Price Target to $4 From $3, Maintains Buy Rating
MT
Transcript : Rigel Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 05, 2024
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q4 Revenue $35.8M, vs. Street Est of $33.4M
MT
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS
AQ
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
PR
B. Riley Lifts Rigel Pharmaceuticals' PT to $1.75 From $1.25 After Announced Purchase of US Rights to Gavreto From Blueprint Medicines; Keeps Neutral Rating
MT
Rigel Pharmaceuticals Seeks Acquisitions
CI
Transcript : Rigel Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 12:00 PM
Rigel Pharmaceuticals Provides Business Update
AQ
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PR
Rigel Pharmaceuticals Enters Collaboration to Study Possible Treatment for Brain Tumors; Shares Rise
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RIGL Stock
  4. News Rigel Pharmaceuticals, Inc.